Tumoral microenvironment
The challenge: metastasis
For more than half a century, science has achieved remarkable advances in the diagnosis and treatment of the early stages of cancer. However, metastatic solid tumors They remain a medically necessary need that is not covered. From the classic drugs of chemotherapy to modern immunotherapies, no approach has effectively treated solid tumors such as colorectal cancer or metastatic pancreatic cancer.
Tumor microenvironment-targeted ADCs
Patients with metastatic colorectal cancer with stable microsatellites (CCR-MSS) respond poorly to immunotherapeutic drugs (N. Engl. J. Med. 372, 2509-2520 (2015). Lancet Oncol. 18, 1182-1191 (2017). No patient with CCR-MSS with hepatic or peritoneal metastases benefits from immunotherapy., Even in combination with tyrosine kinase inhibitors (J. Clin. Oncol. 38, 2053-2061 (2020). JAMA Network Open 4, e2118416 (2021).
Immunotherapy in metastatic pancreatic cancer, either as a single agent or in combination with chemotherapy, It has shown very limited benefits, Except in the rare tumors with defects in DNA mismatch repair. Possible explanations for this immune resistance include factors in the tumor microenvironment, such as the presence of cancer-associated fibroblasts (CAFs) (Renouf, D. J. et al. Nat. Commun. 13, 5020 (2022). O’Reilly, E. M. et al. JAMA Oncol. 5, 1431–1438 (2019). Monteran, L. & Erez, N. Front. Immunol. 10, 1835 (2019).
CAFS
Our approach: Targeting CAFs in the tumor microenvironment
The tumor microenvironment is a complex and heterogeneous network of extracellular matrix, soluble cytokines, chemokines, proteases, cancer-associated fibroblasts, endothelial cells, and immune cells. CAFs in the tumor microenvironment are in constant interaction with tumor cells and play a key role in tumor invasion, growth, metastasis, and immunosuppression.
Oncomatryx has developed Conjugated Antibodies to Drugs (ADCs) that target CAFs in the tumor microenvironment, either as monotherapies or in combination with existing chemotherapies and immunotherapies.
ADC directed against CAFs of Oncomatryx they have a novel mechanism of action, vehiculating cytotoxic drugs and promoting an antitumor immune response.
The ADCs of Oncomatryx directed against CAFs are showing an unparalleled safety profile and potent efficacy in murine models and clinical trials.
QUANTUM IMMUNOTHERAPY
Pioneers in Quantum Immunotherapy
Immunologically-based tumors cold They are characterized by their resistance to immunotherapy. Cancer-associated fibroblasts (CAFs) play a key role by secreting immunosuppressive interleukins in the tumor microenvironment and blocking the infiltration of cytotoxic immune cells.
OMTX705, the first Oncomatryx ADC in clinical trials, redefine this panorama by targeting CAFs to interfere with their immunosuppressive influence. This innovative approach transforms tumors immunologically cold in tumors Hot, allowing the immune cells to infiltrate and attack the tumor.
By blocking the secretion mediated by CAFs of immunosuppressive interleukins and by delivering a cytotoxic load that kills surrounding tumor cells and generates tumor neoantigens, OMTX705 stimulates a robust immune response, closing the cycle to maintain a tumor state Hot.
This revolutionary therapy bridges the gap between immune resistance and immune activation, offering a new horizon in the treatment of cancer.
